| Symbol | ARWR |
|---|---|
| Name | ARROWHEAD PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 177 E. COLORADO BLVD,SUITE 700, PASADENA, California, 91105, United States |
| Telephone | +1 626 - 304-3400 |
| Fax | — |
| — | |
| Website | https://www.arrowheadpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000879407 |
| Description | Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. Additional info from NASDAQ: |
2026-07-22 11:30
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Read more
2026-06-22 16:33
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Read more
2026-06-18 11:30
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
Read more
2026-06-18 01:44
Director Cohen Matthew Gregory 🟢 acquired 11.9K shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Transaction Date: Jun 15, 2026 | Filing ID: 000004
Read more
2026-06-17 22:44
New Form 3 - ARROWHEAD PHARMACEUTICALS, INC. <b>Filed:</b> 2026-06-17 <b>AccNo:</b> 0002141314-26-000003 <b>Size:</b> 4 KB
Read more
2026-06-16 20:02
(99% Neutral) ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Announces New Board Appointment
Read more
2026-05-27 11:00
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Read more
2026-05-26 14:00
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Read more
2026-05-19 17:46
New Form 144/A - ARROWHEAD PHARMACEUTICALS, INC. <b>Filed:</b> 2026-05-19 <b>AccNo:</b> 0001628280-26-036528 <b>Size:</b> 5 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06796426 | Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglycer… | — | Familial Chylomicronemia | Available | — | — | ClinicalTrials.gov |
| NCT06796426 | Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglycer… | — | Familial Chylomicronemia | Available | — | — | ClinicalTrials.gov |
| NCT07473843 | Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercho… | Phase3 | Homozygous Familial Hypercholesterolemia | Not_Yet_Recruiting | 2026-08-01 | 2028-08-01 | ClinicalTrials.gov |
| NCT07473843 | Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercho… | Phase3 | Homozygous Familial Hypercholesterolemia | Not_Yet_Recruiting | 2026-08-01 | 2028-08-01 | ClinicalTrials.gov |
| NCT07662096 | A First-In-Human Study of ARO-033 in Adult Participants | Phase1 | Healthy Participants | Recruiting | 2026-06-25 | 2027-07-18 | ClinicalTrials.gov |
| NCT07662096 | A First-In-Human Study of ARO-033 in Adult Participants | Phase1 | Healthy Participants | Recruiting | 2026-06-25 | 2027-07-18 | ClinicalTrials.gov |
| NCT07241546 | Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma | Phase2 | Asthma | Recruiting | 2026-03-30 | 2028-04-01 | ClinicalTrials.gov |
| NCT07241546 | Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma | Phase2 | Asthma | Recruiting | 2026-03-30 | 2028-04-01 | ClinicalTrials.gov |
| NCT07223658 | Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia | Phase1 | Hyperlipidemia; Mixed | Recruiting | 2025-12-22 | 2027-07-01 | ClinicalTrials.gov |
| NCT07223658 | Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia | Phase1 | Hyperlipidemia; Mixed | Recruiting | 2025-12-22 | 2027-07-01 | ClinicalTrials.gov |
| NCT07221344 | Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzhei… | Phase1 | Alzheimer Disease | Recruiting | 2025-11-18 | 2027-06-01 | ClinicalTrials.gov |
| NCT07221344 | Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzhei… | Phase1 | Alzheimer Disease | Recruiting | 2025-11-18 | 2027-06-01 | ClinicalTrials.gov |
| NCT07037771 | A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous F… | Phase3 | Homozygous Familial Hypercholesterolemia | Recruiting | 2025-06-17 | 2027-08-20 | ClinicalTrials.gov |
| NCT07037771 | A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous F… | Phase3 | Homozygous Familial Hypercholesterolemia | Recruiting | 2025-06-17 | 2027-08-20 | ClinicalTrials.gov |
| NCT06937203 | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type… | Phase1 | Obesity | Recruiting | 2025-05-09 | 2027-02-01 | ClinicalTrials.gov |
| NCT06937203 | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type… | Phase1 | Obesity | Recruiting | 2025-05-09 | 2027-02-01 | ClinicalTrials.gov |
| NCT06880770 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute… | Phase3 | Severe Hypertriglyceridemia | Recruiting | 2025-04-24 | 2029-06-01 | ClinicalTrials.gov |
| NCT06880770 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute… | Phase3 | Severe Hypertriglyceridemia | Recruiting | 2025-04-24 | 2029-06-01 | ClinicalTrials.gov |
| NCT06822790 | Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia | Phase3 | Hypertriglyceridemia | Recruiting | 2025-04-09 | 2028-07-01 | ClinicalTrials.gov |
| NCT06822790 | Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia | Phase3 | Hypertriglyceridemia | Recruiting | 2025-04-09 | 2028-07-01 | ClinicalTrials.gov |
| NCT06672445 | Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 | Phase1 | Spinocerebellar Ataxia Type 2 | Active_Not_Recruiting | 2024-12-17 | 2026-12-01 | ClinicalTrials.gov |
| NCT06672445 | Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 | Phase1 | Spinocerebellar Ataxia Type 2 | Active_Not_Recruiting | 2024-12-17 | 2026-12-01 | ClinicalTrials.gov |
| NCT06700538 | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Typ… | Phase1 | Obesity | Recruiting | 2024-12-04 | 2028-01-17 | ClinicalTrials.gov |
| NCT06700538 | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Typ… | Phase1 | Obesity | Recruiting | 2024-12-04 | 2028-01-17 | ClinicalTrials.gov |
| NCT06827288 | Adaptive Interventions for Emergency Department Patients With Opioid Use Disord… | Na | Opioid Use Disorder | Recruiting | 2024-10-04 | 2028-03-31 | ClinicalTrials.gov |
| NCT06827288 | Adaptive Interventions for Emergency Department Patients With Opioid Use Disord… | Na | Opioid Use Disorder | Recruiting | 2024-10-04 | 2028-03-31 | ClinicalTrials.gov |
| NCT06347016 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia | Phase3 | Severe Hypertriglyceridemia | Active_Not_Recruiting | 2024-07-23 | 2026-09-01 | ClinicalTrials.gov |
| NCT06347016 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia | Phase3 | Severe Hypertriglyceridemia | Active_Not_Recruiting | 2024-07-23 | 2026-09-01 | ClinicalTrials.gov |
| NCT06347003 | Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia | Phase3 | Severe Hypertriglyceridemia | Active_Not_Recruiting | 2024-07-22 | 2026-09-01 | ClinicalTrials.gov |
| NCT06347003 | Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia | Phase3 | Severe Hypertriglyceridemia | Active_Not_Recruiting | 2024-07-22 | 2026-09-01 | ClinicalTrials.gov |
| NCT06347133 | Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia | Phase3 | Hypertriglyceridemia | Active_Not_Recruiting | 2024-05-21 | 2026-09-01 | ClinicalTrials.gov |
| NCT06347133 | Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia | Phase3 | Hypertriglyceridemia | Active_Not_Recruiting | 2024-05-21 | 2026-09-01 | ClinicalTrials.gov |
| NCT07056062 | Oral Calcium Supplementation in Labor | Phase2 | Uterine Contraction | Completed | 2024-04-30 | 2025-05-30 | ClinicalTrials.gov |
| NCT07056062 | Oral Calcium Supplementation in Labor | Phase2 | Uterine Contraction | Completed | 2024-04-30 | 2025-05-30 | ClinicalTrials.gov |
| NCT06209177 | Study of ARO-CFB in Adult Healthy Volunteers | Phase1 | IgA Nephropathy | Completed | 2024-04-05 | 2026-03-06 | ClinicalTrials.gov |
| NCT06209177 | Study of ARO-CFB in Adult Healthy Volunteers | Phase1 | IgA Nephropathy | Completed | 2024-04-05 | 2026-03-06 | ClinicalTrials.gov |
| NCT06138743 | Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy | Phase1 | Myotonic Dystrophy 1 | Recruiting | 2024-03-04 | 2026-12-01 | ClinicalTrials.gov |
| NCT06138743 | Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy | Phase1 | Myotonic Dystrophy 1 | Recruiting | 2024-03-04 | 2026-12-01 | ClinicalTrials.gov |
| NCT06131983 | Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Mus… | Phase1 | Facio-Scapulo-Humeral Dystrophy | Recruiting | 2024-02-22 | 2026-12-01 | ClinicalTrials.gov |
| NCT06131983 | Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Mus… | Phase1 | Facio-Scapulo-Humeral Dystrophy | Recruiting | 2024-02-22 | 2026-12-01 | ClinicalTrials.gov |
| NCT05949294 | Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) | Phase1 | Amyotrophic Lateral Sclerosis | Withdrawn | 2024-01-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT05949294 | Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) | Phase1 | Amyotrophic Lateral Sclerosis | Withdrawn | 2024-01-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT06366698 | Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia | Phase3 | Iron Deficiency Anemia of Pregnancy | Unknown | 2023-11-21 | 2025-12-30 | ClinicalTrials.gov |
| NCT06366698 | Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia | Phase3 | Iron Deficiency Anemia of Pregnancy | Unknown | 2023-11-21 | 2025-12-30 | ClinicalTrials.gov |
| NCT06543290 | Azithromycin Before Induction | Phase1 | Infections | Recruiting | 2023-08-07 | 2026-08-07 | ClinicalTrials.gov |
| NCT06543290 | Azithromycin Before Induction | Phase1 | Infections | Recruiting | 2023-08-07 | 2026-08-07 | ClinicalTrials.gov |
| NCT05400382 | Mindfulness to Reduce Post-cesarean Pain and Prevent Postpartum Depression | Na | Depression, Unipolar | Unknown | 2023-07-01 | 2026-03-31 | ClinicalTrials.gov |
| NCT05400382 | Mindfulness to Reduce Post-cesarean Pain and Prevent Postpartum Depression | Na | Depression, Unipolar | Unknown | 2023-07-01 | 2026-03-31 | ClinicalTrials.gov |
| NCT05537025 | Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idi… | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2023-01-30 | 2025-09-05 | ClinicalTrials.gov |
| NCT05537025 | Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idi… | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2023-01-30 | 2025-09-05 | ClinicalTrials.gov |
| NCT05533294 | Study of ARO-RAGE in Healthy Subjects | Phase1 | Asthma | Completed | 2022-11-29 | 2024-02-08 | ClinicalTrials.gov |
| NCT05533294 | Study of ARO-RAGE in Healthy Subjects | Phase1 | Asthma | Completed | 2022-11-29 | 2024-02-08 | ClinicalTrials.gov |
| NCT05859958 | ABO Blood Group Type Association With COVID-19 Severity | — | COVID-19 | Completed | 2022-11-10 | 2023-05-10 | ClinicalTrials.gov |
| NCT05859958 | ABO Blood Group Type Association With COVID-19 Severity | — | COVID-19 | Completed | 2022-11-10 | 2023-05-10 | ClinicalTrials.gov |
| NCT05413135 | Study of ARO-APOC3 in Adults With Dyslipidemia | Phase2 | Dyslipidemias | Completed | 2022-07-07 | 2025-09-22 | ClinicalTrials.gov |
| NCT05413135 | Study of ARO-APOC3 in Adults With Dyslipidemia | Phase2 | Dyslipidemias | Completed | 2022-07-07 | 2025-09-22 | ClinicalTrials.gov |
| NCT05276570 | Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disea… | Phase1 | Asthma | Completed | 2022-06-29 | 2025-04-16 | ClinicalTrials.gov |
| NCT05276570 | Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disea… | Phase1 | Asthma | Completed | 2022-06-29 | 2025-04-16 | ClinicalTrials.gov |
| NCT05292950 | Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung… | Phase1 | Asthma | Terminated | 2022-06-27 | 2024-11-12 | ClinicalTrials.gov |
| NCT05292950 | Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung… | Phase1 | Asthma | Terminated | 2022-06-27 | 2024-11-12 | ClinicalTrials.gov |
| NCT05217667 | Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia… | Phase2 | Homozygous Familial Hypercholesterolemia | Terminated | 2022-04-22 | 2025-11-13 | ClinicalTrials.gov |
| NCT05217667 | Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia… | Phase2 | Homozygous Familial Hypercholesterolemia | Terminated | 2022-04-22 | 2025-11-13 | ClinicalTrials.gov |
| NCT05083364 | Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediat… | Phase1 | C3 Glomerulopathy | Completed | 2022-02-01 | 2025-09-10 | ClinicalTrials.gov |
| NCT05083364 | Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediat… | Phase1 | C3 Glomerulopathy | Completed | 2022-02-01 | 2025-09-10 | ClinicalTrials.gov |
| NCT05089084 | Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrom… | Phase3 | Familial Chylomicronemia | Completed | 2021-12-14 | 2026-04-21 | ClinicalTrials.gov |
| NCT05089084 | Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrom… | Phase3 | Familial Chylomicronemia | Completed | 2021-12-14 | 2026-04-21 | ClinicalTrials.gov |
| NCT05897528 | Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 I… | — | COVID-19 | Completed | 2021-10-14 | 2022-12-30 | ClinicalTrials.gov |
| NCT05897528 | Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 I… | — | COVID-19 | Completed | 2021-10-14 | 2022-12-30 | ClinicalTrials.gov |
| NCT04998201 | Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia | Phase2 | Mixed Dyslipidemia | Completed | 2021-09-28 | 2023-08-14 | ClinicalTrials.gov |
| NCT04998201 | Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia | Phase2 | Mixed Dyslipidemia | Completed | 2021-09-28 | 2023-08-14 | ClinicalTrials.gov |
| NCT04832971 | Study of ARO-ANG3 in Adults With Mixed Dyslipidemia | Phase2 | Mixed Dyslipidemia | Completed | 2021-06-28 | 2024-09-25 | ClinicalTrials.gov |
| NCT04832971 | Study of ARO-ANG3 in Adults With Mixed Dyslipidemia | Phase2 | Mixed Dyslipidemia | Completed | 2021-06-28 | 2024-09-25 | ClinicalTrials.gov |
| NCT04720534 | Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia | Phase2 | Severe Hypertriglyceridemia | Completed | 2021-05-31 | 2023-08-31 | ClinicalTrials.gov |
| NCT04720534 | Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia | Phase2 | Severe Hypertriglyceridemia | Completed | 2021-05-31 | 2023-08-31 | ClinicalTrials.gov |
| NCT05611398 | Lactate Monitoring in Traumatic Long Bone Fractures Requiring Emergent Surgical… | — | Lactate Blood Increase | Completed | 2021-01-01 | 2022-01-01 | ClinicalTrials.gov |
| NCT05611398 | Lactate Monitoring in Traumatic Long Bone Fractures Requiring Emergent Surgical… | — | Lactate Blood Increase | Completed | 2021-01-01 | 2022-01-01 | ClinicalTrials.gov |
| NCT05612867 | Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vi… | — | Burns | Completed | 2020-12-12 | 2021-01-08 | ClinicalTrials.gov |
| NCT05612867 | Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vi… | — | Burns | Completed | 2020-12-12 | 2021-01-08 | ClinicalTrials.gov |
| NCT05888363 | Management and Removal of Foreign Bodies in the Emergency Department | — | Rectal Foreign Body | Completed | 2020-12-08 | 2021-12-08 | ClinicalTrials.gov |
| NCT05888363 | Management and Removal of Foreign Bodies in the Emergency Department | — | Rectal Foreign Body | Completed | 2020-12-08 | 2021-12-08 | ClinicalTrials.gov |
| NCT04169711 | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma | Phase1 | Clear Cell Renal Cell Carcinoma | Completed | 2020-08-17 | 2022-07-22 | ClinicalTrials.gov |
| NCT04169711 | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma | Phase1 | Clear Cell Renal Cell Carcinoma | Completed | 2020-08-17 | 2022-07-22 | ClinicalTrials.gov |
| NCT04375514 | Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis | Phase1 | Cystic Fibrosis, Pulmonary | Terminated | 2020-07-30 | 2022-05-13 | ClinicalTrials.gov |
| NCT04375514 | Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis | Phase1 | Cystic Fibrosis, Pulmonary | Terminated | 2020-07-30 | 2022-05-13 | ClinicalTrials.gov |
| NCT03936361 | Statins In Intracerbral Hemorrhage | Phase3 | Intracerebral Hemorrhage | Recruiting | 2020-06-10 | 2029-12-01 | ClinicalTrials.gov |
| NCT03936361 | Statins In Intracerbral Hemorrhage | Phase3 | Intracerebral Hemorrhage | Recruiting | 2020-06-10 | 2029-12-01 | ClinicalTrials.gov |
| NCT04202354 | Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohe… | Phase1 | Non-alcoholic Steatohepatitis | Completed | 2020-03-03 | 2021-09-03 | ClinicalTrials.gov |
| NCT04202354 | Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohe… | Phase1 | Non-alcoholic Steatohepatitis | Completed | 2020-03-03 | 2021-09-03 | ClinicalTrials.gov |
| NCT05964088 | Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critic… | — | Acute Kidney Injury | Completed | 2020-03-01 | 2022-02-12 | ClinicalTrials.gov |
| NCT05964088 | Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critic… | — | Acute Kidney Injury | Completed | 2020-03-01 | 2022-02-12 | ClinicalTrials.gov |
| NCT03946449 | Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Def… | Phase2 | Alpha 1-Antitrypsin Deficiency | Completed | 2019-10-31 | 2023-12-14 | ClinicalTrials.gov |
| NCT03946449 | Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Def… | Phase2 | Alpha 1-Antitrypsin Deficiency | Completed | 2019-10-31 | 2023-12-14 | ClinicalTrials.gov |
| NCT03945292 | Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) | Phase2 | Alpha 1-Antitrypsin Deficiency | Completed | 2019-08-07 | 2023-09-18 | ClinicalTrials.gov |
| NCT03945292 | Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) | Phase2 | Alpha 1-Antitrypsin Deficiency | Completed | 2019-08-07 | 2023-09-18 | ClinicalTrials.gov |
| NCT03783377 | Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Pat… | Phase1 | Hypertriglyceridemia | Completed | 2019-03-08 | 2021-02-11 | ClinicalTrials.gov |
| NCT03783377 | Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Pat… | Phase1 | Hypertriglyceridemia | Completed | 2019-03-08 | 2021-02-11 | ClinicalTrials.gov |
| NCT03747224 | Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients | Phase1 | Dyslipidemias | Completed | 2019-01-07 | 2021-05-17 | ClinicalTrials.gov |
| NCT03747224 | Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients | Phase1 | Dyslipidemias | Completed | 2019-01-07 | 2021-05-17 | ClinicalTrials.gov |
| NCT03365947 | Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus… | Phase1 | Hepatitis B | Completed | 2018-03-27 | 2020-04-23 | ClinicalTrials.gov |
| NCT03365947 | Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus… | Phase1 | Hepatitis B | Completed | 2018-03-27 | 2020-04-23 | ClinicalTrials.gov |
| NCT03362242 | Study of ARO-AAT in Normal Adult Volunteers | Phase1 | Alpha 1-Antitrypsin Deficiency | Completed | 2018-03-12 | 2020-03-21 | ClinicalTrials.gov |
| NCT03362242 | Study of ARO-AAT in Normal Adult Volunteers | Phase1 | Alpha 1-Antitrypsin Deficiency | Completed | 2018-03-12 | 2020-03-21 | ClinicalTrials.gov |
| NCT02900183 | Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahe… | Phase2 | Alpha-1 Antitrypsin Deficiency | Withdrawn | 2016-10-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02900183 | Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahe… | Phase2 | Alpha-1 Antitrypsin Deficiency | Withdrawn | 2016-10-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02797522 | A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chron… | Phase1 | Hepatitis B | Terminated | 2016-06-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02797522 | A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chron… | Phase1 | Hepatitis B | Terminated | 2016-06-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02738008 | Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in… | Phase2 | Hepatitis B | Terminated | 2016-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02738008 | Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in… | Phase2 | Hepatitis B | Terminated | 2016-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02577029 | Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic C… | Phase2 | Hepatitis B | Terminated | 2015-12-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02577029 | Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic C… | Phase2 | Hepatitis B | Terminated | 2015-12-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02604212 | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) … | Phase2 | Hepatitis B | Terminated | 2015-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02604212 | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) … | Phase2 | Hepatitis B | Terminated | 2015-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02604199 | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) … | Phase2 | Hepatitis B | Terminated | 2015-09-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02535416 | A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers | Phase1 | Healthy | Completed | 2015-09-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02535416 | A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers | Phase1 | Healthy | Completed | 2015-09-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02604199 | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) … | Phase2 | Hepatitis B | Terminated | 2015-09-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02452528 | Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Posit… | Phase2 | Chronic Hepatitis B | Terminated | 2015-08-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02452528 | Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Posit… | Phase2 | Chronic Hepatitis B | Terminated | 2015-08-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT03469947 | California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA | Phase3 | Hemorrhagic Shock | Completed | 2015-03-01 | 2024-07-29 | ClinicalTrials.gov |
| NCT03469947 | California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA | Phase3 | Hemorrhagic Shock | Completed | 2015-03-01 | 2024-07-29 | ClinicalTrials.gov |
| NCT02349126 | Study of ARC-520 in Patient With Chronic Hepatitis B Virus | Phase2 | Chronic Hepatitis B | Withdrawn | 2015-02-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02363946 | A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Anti… | Phase1 | Alpha-1 Antitrypsin Deficiency | Terminated | 2015-02-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02349126 | Study of ARC-520 in Patient With Chronic Hepatitis B Virus | Phase2 | Chronic Hepatitis B | Withdrawn | 2015-02-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02363946 | A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Anti… | Phase1 | Alpha-1 Antitrypsin Deficiency | Terminated | 2015-02-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02485262 | Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience | — | Hepatitis C | Unknown | 2013-11-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02485262 | Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience | — | Hepatitis C | Unknown | 2013-11-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT01872065 | Safety and Tolerability Study of ARC-520 in Healthy Volunteers | Phase1 | Healthy | Completed | 2013-07-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01872065 | Safety and Tolerability Study of ARC-520 in Healthy Volunteers | Phase1 | Healthy | Completed | 2013-07-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01736449 | Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management | Phase4 | Pterygium | Completed | 2011-04-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01736449 | Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management | Phase4 | Pterygium | Completed | 2011-04-01 | 2012-04-01 | ClinicalTrials.gov |
Total clinical trials: 130
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07662096 |
| ARO-033 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07662096 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | NCT06347003 |
| Plozasiran Injection | Other | Phase PHASE3 | Severe Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | NCT06347003 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06937203 |
| ARO-ALK7 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06937203 |
| Placebo | Other | Phase PHASE1 | Hyperlipidemia; Mixed | RECRUITING | NCT07223658 |
| ARO-DIMERPA | Other | Phase PHASE1 | Hyperlipidemia; Mixed | RECRUITING | NCT07223658 |
| Placebo | Other | Phase PHASE1 | Spinocerebellar Ataxia Type 2 | ACTIVE_NOT_RECRUITING | NCT06672445 |
| ARO-ATXN2 Injection | Other | Phase PHASE1 | Spinocerebellar Ataxia Type 2 | ACTIVE_NOT_RECRUITING | NCT06672445 |
| Placebo | Other | Phase PHASE3 | Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | NCT06347133 |
| Plozasiran Injection | Other | Phase PHASE3 | Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | NCT06347133 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE2 | Asthma | RECRUITING | NCT07241546 |
| ARO-RAGE | Other | Phase PHASE2 | Asthma | RECRUITING | NCT07241546 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | NOT_YET_RECRUITING | NCT07662096 |
| ARO-033 | Other | Phase PHASE1 | Healthy Participants | NOT_YET_RECRUITING | NCT07662096 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease | RECRUITING | NCT07221344 |
| ARO-MAPT-SC | Other | Phase PHASE1 | Alzheimer Disease | RECRUITING | NCT07221344 |
| Placebo | Other | Phase PHASE1 | Hyperlipidemia; Mixed | RECRUITING | NCT07223658 |
| ARO-DIMERPA | Other | Phase PHASE1 | Hyperlipidemia; Mixed | RECRUITING | NCT07223658 |
| ARO-ANG 3 Injection | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | TERMINATED | NCT05217667 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Familial Chylomicronemia | COMPLETED | NCT05089084 |
| Plozasiran | Other | Phase PHASE3 | Familial Chylomicronemia | COMPLETED | NCT05089084 |
| Plozasiran Injection | Other | Phase PHASE3 | Hypertriglyceridemia | RECRUITING | NCT06822790 |
| Zodasiran | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | NOT_YET_RECRUITING | NCT07473843 |
| Placebo | Other | Phase PHASE2 | Asthma | RECRUITING | NCT07241546 |
| ARO-RAGE | Other | Phase PHASE2 | Asthma | RECRUITING | NCT07241546 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease | RECRUITING | NCT07221344 |
| ARO-MAPT-SC | Other | Phase PHASE1 | Alzheimer Disease | RECRUITING | NCT07221344 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-ANG 3 Injection | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | TERMINATED | NCT05217667 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-ANG 3 Injection | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | TERMINATED | NCT05217667 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-ANG 3 Injection | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | TERMINATED | NCT05217667 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-ANG 3 Injection | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | TERMINATED | NCT05217667 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-ANG 3 Injection | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | TERMINATED | NCT05217667 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | COMPLETED | NCT06209177 |
| ARO-APOC3 | Other | Phase PHASE2 | Dyslipidemias | COMPLETED | NCT05413135 |
| ARO-APOC3 | Other | Phase PHASE2 | Dyslipidemias | COMPLETED | NCT05413135 |
| ARO-APOC3 | Other | Phase PHASE2 | Dyslipidemias | COMPLETED | NCT05413135 |
| ARO-APOC3 | Other | Phase PHASE2 | Dyslipidemias | COMPLETED | NCT05413135 |
| ARO-APOC3 | Other | Phase PHASE2 | Dyslipidemias | COMPLETED | NCT05413135 |
| ARO-APOC3 | Other | Phase PHASE2 | Dyslipidemias | COMPLETED | NCT05413135 |
| Plozasiran Injection | Other | Phase PHASE3 | Hypertriglyceridemia | RECRUITING | NCT06822790 |
| Plozasiran Injection | Other | Phase PHASE3 | Hypertriglyceridemia | RECRUITING | NCT06822790 |
| Plozasiran Injection | Other | Phase PHASE3 | Hypertriglyceridemia | RECRUITING | NCT06822790 |
| Plozasiran Injection | Other | Phase PHASE3 | Hypertriglyceridemia | RECRUITING | NCT06822790 |
| Plozasiran Injection | Other | Phase PHASE3 | Hypertriglyceridemia | RECRUITING | NCT06822790 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Orthopedic Surgery | Procedure | Preclinical | Lactate Blood Increase | COMPLETED | NCT05611398 |
| Bevacizumab | Other | Phase PHASE4 | Pterygium | COMPLETED | NCT01736449 |
| Sofosbuvir and simeprevir | Other | Preclinical | Hepatitis C | UNKNOWN | NCT02485262 |
| Mindfulness | Other | Approved | Depression, Unipolar | UNKNOWN | NCT05400382 |
| Vitamin C | Other | Preclinical | Burns | COMPLETED | NCT05612867 |
| No Intervention | Other | Preclinical | COVID-19 | COMPLETED | NCT05859958 |
| No Intervention | Other | Preclinical | Rectal Foreign Body | COMPLETED | NCT05888363 |
| No Intervention | Other | Preclinical | COVID-19 | COMPLETED | NCT05897528 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT05533294 |
| ARO-RAGE Injection | Other | Phase PHASE1 | Asthma | COMPLETED | NCT05533294 |
| Ferrous sulfate | Other | Phase PHASE3 | Iron Deficiency Anemia of Pregnancy | UNKNOWN | NCT06366698 |
| Venofer 200 MG Per 10 ML Injection | Other | Phase PHASE3 | Iron Deficiency Anemia of Pregnancy | UNKNOWN | NCT06366698 |
| ARO-SOD1 Injection | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | WITHDRAWN | NCT05949294 |
| Tranexamic Acid | Other | Phase PHASE3 | Hemorrhagic Shock | COMPLETED | NCT03469947 |
| Calcium carbonate | Other | Phase PHASE2 | Uterine Contraction | COMPLETED | NCT07056062 |
| Placebo | Other | Phase PHASE1 | Infections | RECRUITING | NCT06543290 |
| Azithromycin Pill | Other | Phase PHASE1 | Infections | RECRUITING | NCT06543290 |
| Zodasiran | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | NOT_YET_RECRUITING | NCT07473843 |
| Placebo | Other | Phase PHASE2 | Asthma | RECRUITING | NCT07241546 |
| ARO-RAGE | Other | Phase PHASE2 | Asthma | RECRUITING | NCT07241546 |
| Plozasiran Injection | Other | Phase PHASE3 | Hypertriglyceridemia | RECRUITING | NCT06822790 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| sterile normal saline (0.9% NaCl) | Other | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT04202354 |
| ARO-HSD Injection | Other | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT04202354 |
| Placebo | Other | Phase PHASE3 | Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | NCT06347133 |
| Plozasiran Injection | Other | Phase PHASE3 | Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | NCT06347133 |
| ARO-HIF2 | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | COMPLETED | NCT04169711 |
| ARO-ANG 3 Injection | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | ACTIVE_NOT_RECRUITING | NCT05217667 |
| Placebo | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05537025 |
| ARO-MMP7 Inhalation Solution | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05537025 |
| ARO-AAT | Other | Phase PHASE2 | Alpha 1-Antitrypsin Deficiency | COMPLETED | NCT03946449 |
| JNJ-56136379 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT03365947 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT03365947 |
| ARO-HBV | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT03365947 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | NCT06347016 |
| Plozasiran Injection | Other | Phase PHASE3 | Severe Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | NCT06347016 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | NCT06347003 |
| Plozasiran Injection | Other | Phase PHASE3 | Severe Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | NCT06347003 |
| diphenhydramine | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT02452528 |
| Tenofovir | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT02452528 |
| Entecavir | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT02452528 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT02452528 |
| ARC-520 | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT02452528 |
| Placebo | Other | Phase PHASE2 | Alpha 1-Antitrypsin Deficiency | COMPLETED | NCT03945292 |
| Fazisiran Injection | Other | Phase PHASE2 | Alpha 1-Antitrypsin Deficiency | COMPLETED | NCT03945292 |
| Placebo | Other | Phase PHASE1 | Asthma | TERMINATED | NCT05292950 |
| ARO-MUC5AC | Other | Phase PHASE1 | Asthma | TERMINATED | NCT05292950 |
| Placebo Subcutaneous (SC) Injection | Other | Phase PHASE1 | Myotonic Dystrophy 1 | RECRUITING | NCT06138743 |
| ARO-DM1 subcutaneous (SC) injection | Other | Phase PHASE1 | Myotonic Dystrophy 1 | RECRUITING | NCT06138743 |
| Placebo Intravenous (IV) Infusion | Other | Phase PHASE1 | Myotonic Dystrophy 1 | RECRUITING | NCT06138743 |
| ARO-DM1 Intravenous (IV) Infusion | Other | Phase PHASE1 | Myotonic Dystrophy 1 | RECRUITING | NCT06138743 |
| Placebo | Other | Phase PHASE2 | Mixed Dyslipidemia | COMPLETED | NCT04832971 |
| ARO-ANG3 | Other | Phase PHASE2 | Mixed Dyslipidemia | COMPLETED | NCT04832971 |
| ARO-APOC3 | Other | Phase PHASE2 | Dyslipidemias | COMPLETED | NCT05413135 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis, Pulmonary | TERMINATED | NCT04375514 |
| ARO-ENaC | Other | Phase PHASE1 | Cystic Fibrosis, Pulmonary | TERMINATED | NCT04375514 |
| ARC-AAT Injection | Other | Phase PHASE2 | Alpha-1 Antitrypsin Deficiency | WITHDRAWN | NCT02900183 |
| sterile normal saline (0.9% NaCl) | Other | Phase PHASE1 | Hypertriglyceridemia | COMPLETED | NCT03783377 |
| ARO-APOC3 | Other | Phase PHASE1 | Hypertriglyceridemia | COMPLETED | NCT03783377 |
| sterile normal saline (0.9% NaCl) | Other | Phase PHASE1 | Dyslipidemias | COMPLETED | NCT03747224 |
| ARO-ANG3 | Other | Phase PHASE1 | Dyslipidemias | COMPLETED | NCT03747224 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | COMPLETED | NCT03362242 |
| ARO-AAT Injection | Other | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | COMPLETED | NCT03362242 |
| ARC-520 Injection | Other | Phase PHASE2 | Chronic Hepatitis B | WITHDRAWN | NCT02349126 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01872065 |
| ARC-520 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01872065 |
| Placebo | Other | Phase PHASE1 | Hyperlipidemia; Mixed | RECRUITING | NCT07223658 |
| ARO-DIMERPA | Other | Phase PHASE1 | Hyperlipidemia; Mixed | RECRUITING | NCT07223658 |
| tenofovir | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT02797522 |
| entecavir | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT02797522 |
| acetaminophen | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT02797522 |
| antihistamine | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT02797522 |
| Placebo | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT02797522 |
| ARC-521 Injection | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT02797522 |
| Diphenhydramine | Other | Phase PHASE1 | Alpha-1 Antitrypsin Deficiency | TERMINATED | NCT02363946 |
| Placebo | Other | Phase PHASE1 | Alpha-1 Antitrypsin Deficiency | TERMINATED | NCT02363946 |
| ARC-AAT Injection | Other | Phase PHASE1 | Alpha-1 Antitrypsin Deficiency | TERMINATED | NCT02363946 |
| antihistamine | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02738008 |
| tenofovir | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02738008 |
| entecavir | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02738008 |
| ARC-520 Injection | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02738008 |
| tenofovir | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02604212 |
| antihistamine | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02604212 |
| entecavir | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02604212 |
| Placebo | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02604212 |
| ARC-520 | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02604212 |
| antihistamine | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02604199 |
| tenofovir | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02604199 |
| entecavir | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02604199 |
| placebo | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02604199 |
| ARC-520 Injection | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02604199 |
| antihistamine | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02577029 |
| tenofovir disoproxil | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02577029 |
| pegylated interferon alpha 2a | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02577029 |
| entecavir | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02577029 |
| ARC-520 | Other | Phase PHASE2 | Hepatitis B | TERMINATED | NCT02577029 |
| diphenhydramine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02535416 |
| cetirizine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02535416 |
| ARC-520 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02535416 |
| Placebo | Other | Phase PHASE3 | Familial Chylomicronemia | ACTIVE_NOT_RECRUITING | NCT05089084 |
| Plozasiran | Other | Phase PHASE3 | Familial Chylomicronemia | ACTIVE_NOT_RECRUITING | NCT05089084 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Plozasiran | Other | Phase PHASE3 | Severe Hypertriglyceridemia | RECRUITING | NCT06880770 |
| Placebo | Other | Phase PHASE1 | Spinocerebellar Ataxia Type 2 | RECRUITING | NCT06672445 |
| ARO-ATXN2 Injection | Other | Phase PHASE1 | Spinocerebellar Ataxia Type 2 | RECRUITING | NCT06672445 |
| Placebo | Other | Phase PHASE1 | Facio-Scapulo-Humeral Dystrophy | RECRUITING | NCT06131983 |
| ARO-DUX4 for Injection | Other | Phase PHASE1 | Facio-Scapulo-Humeral Dystrophy | RECRUITING | NCT06131983 |
| ED-ITT + BHS | Other | Approved | Opioid Use Disorder | RECRUITING | NCT06827288 |
| ED-ITT | Other | Approved | Opioid Use Disorder | RECRUITING | NCT06827288 |
| SUN + Telebridge | Other | Approved | Opioid Use Disorder | RECRUITING | NCT06827288 |
| SUN | Other | Approved | Opioid Use Disorder | RECRUITING | NCT06827288 |
| Plozasiran | Other | Preclinical | Familial Chylomicronemia | AVAILABLE | NCT06796426 |
| Placebo | Other | Phase PHASE1 | IgA Nephropathy | ACTIVE_NOT_RECRUITING | NCT06209177 |
| ARO-CFB | Other | Phase PHASE1 | IgA Nephropathy | ACTIVE_NOT_RECRUITING | NCT06209177 |
| Placebo | Other | Phase PHASE2 | Severe Hypertriglyceridemia | COMPLETED | NCT04720534 |
| ARO-APOC3 | Other | Phase PHASE2 | Severe Hypertriglyceridemia | COMPLETED | NCT04720534 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| zodasiran Injection | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | RECRUITING | NCT07037771 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT05276570 |
| ARO-RAGE | Other | Phase PHASE1 | Asthma | COMPLETED | NCT05276570 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06937203 |
| ARO-ALK7 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06937203 |
| Placebo | Other | Phase PHASE2 | Mixed Dyslipidemia | COMPLETED | NCT04998201 |
| ARO-APOC3 | Other | Phase PHASE2 | Mixed Dyslipidemia | COMPLETED | NCT04998201 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease | RECRUITING | NCT07221344 |
| ARO-MAPT-SC | Other | Phase PHASE1 | Alzheimer Disease | RECRUITING | NCT07221344 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Placebo | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| ARO-C3 | Other | Phase PHASE1 | C3 Glomerulopathy | COMPLETED | NCT05083364 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
Total products: 339